BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36974566)

  • 21. Screening, identification of prostate cancer urinary biomarkers and verification of important spots.
    Zhao H; Zhao X; Lei T; Zhang M
    Invest New Drugs; 2019 Oct; 37(5):935-947. PubMed ID: 30610587
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Early diagnosis of prostate cancer by combined use of Trp-p8 expression and PSA density of the transition zone].
    Zhang XS; Zhang Y; Wu PX; Liu SJ; Zhou JY; Liu SX
    Zhonghua Nan Ke Xue; 2015 Aug; 21(8):724-8. PubMed ID: 26442301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection Biomarkers.
    Tsoi TH; Chan CF; Chan WL; Chiu KF; Wong WT; Ng CF; Wong KL
    PLoS One; 2016; 11(9):e0162217. PubMed ID: 27598335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Role of Urinary miRNAs in the Diagnosis, Management and Follow- Up of Prostatic Cancer.
    Ziogou A; Giannakodimos A; Giannakodimos I
    Microrna; 2023; 12(2):83-86. PubMed ID: 36999432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Challenges in Cancer Biomarker Discovery Exemplified by the Identification of Diagnostic MicroRNAs in Prostate Tissues.
    Ambrozkiewicz F; Karczmarski J; Kulecka M; Paziewska A; Cybulska M; Szymanski M; Dobruch J; Antoniewicz A; Mikula M; Ostrowski J
    Biomed Res Int; 2020; 2020():9086829. PubMed ID: 32462034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Copy number variation of urine exfoliated cells by low-coverage whole genome sequencing for diagnosis of prostate adenocarcinoma: a prospective cohort study.
    Guan Y; Wang X; Guan K; Wang D; Bi X; Xiao Z; Xiao Z; Shan X; Hu L; Ma J; Li C; Zhang Y; Shou J; Wang B; Qian Z; Xing N
    BMC Med Genomics; 2022 May; 15(Suppl 2):104. PubMed ID: 35513884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate cancer antigen 3 gene expression in peripheral blood and urine sediments from prostate cancer and benign prostatic hyperplasia patients versus healthy individuals.
    Moradi Sardareh H; Goodarzi MT; Yadegar-Azari R; Poorolajal J; Mousavi-Bahar SH; Saidijam M
    Urol J; 2014 Nov; 11(6):1952-8. PubMed ID: 25433473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deregulation of miR-10b and miR-21 Correlate with Cancer Stem Cells Expansion through the Apoptotic Pathway in Prostate Cancer.
    Shukla KK; Choudhary GR; Sankanagoudar S; Misra S; Vishnoi JR; Pareek P; Pilla KK; Pandey SN; Sharma P
    Asian Pac J Cancer Prev; 2023 Jun; 24(6):2105-2119. PubMed ID: 37378942
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate Specific Antigen, Mean Platelet Volume, and Platelet Distribution Width in Combination to Discriminate Prostate Cancer from Benign Prostate Hyperplasia.
    Fu S; Zhang X; Niu Y; Wang RT
    Asian Pac J Cancer Prev; 2018 Mar; 19(3):699-702. PubMed ID: 29580043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
    Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
    Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CHRDL1, NEFH, TAGLN and SYNM as novel diagnostic biomarkers of benign prostatic hyperplasia and prostate cancer.
    Su Z; Wang G; Li L
    Cancer Biomark; 2023; 38(2):143-159. PubMed ID: 37781794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MicroRNA-21 in peripheral blood mononuclear cells as a novel biomarker in the diagnosis and prognosis of prostate cancer.
    Yang B; Liu Z; Ning H; Zhang K; Pan D; Ding K; Huang W; Kang XL; Wang Y; Chen X
    Cancer Biomark; 2016 Jul; 17(2):223-30. PubMed ID: 27434290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determination of miRNA expression profile in patients with prostate cancer and benign prostate hyperplasia.
    Sancer O; Koşar PA; Tefebaşı MY; Ergün O; Demir M; Koşar A
    Turk J Med Sci; 2022 Jun; 52(3):788-795. PubMed ID: 36326314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Candidate diagnostic miRNAs that can detect cancer in prostate biopsy.
    Paziewska A; Mikula M; Dabrowska M; Kulecka M; Goryca K; Antoniewicz A; Dobruch J; Borowka A; Rutkowski P; Ostrowski J
    Prostate; 2018 Feb; 78(3):178-185. PubMed ID: 29226351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular Diagnostic of Prostate Cancer From Body Fluids Using Methylation-Specific PCR (MS-PCR) Method.
    Minciu R; Dumache R; Gheorghe P; Daminescu L; Rogobete AF; Ionescu D
    Clin Lab; 2016; 62(6):1183-6. PubMed ID: 27468582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
    Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
    Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate health index and prostate cancer gene 3 score but not percent-free Prostate Specific Antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy.
    De Luca S; Passera R; Fiori C; Bollito E; Cappia S; Mario Scarpa R; Sottile A; Franco Randone D; Porpiglia F
    Urol Oncol; 2015 Oct; 33(10):424.e17-23. PubMed ID: 26162485
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer.
    Kachakova D; Mitkova A; Popov E; Popov I; Vlahova A; Dikov T; Christova S; Mitev V; Slavov C; Kaneva R
    DNA Cell Biol; 2015 Mar; 34(3):189-200. PubMed ID: 25521481
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IMPORTANCE OF APOPTOSIS MARKERS (MDM2, BCL-2 AND Bax) IN BENIGN PROSTATIC HYPERPLASIA AND PROSTATE CANCER.
    Saker Z; Tsintsadze O; Jiqia I; Managadze L; Chkhotua A
    Georgian Med News; 2015 Dec; (249):7-14. PubMed ID: 26719543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MMP26: A potential biomarker for prostate cancer.
    Cheng T; Li F; Wei R; Lv MQ; Zhou Y; Dai Y; Yuan Y; Jiang GY; Ma D; Gao QL
    J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):891-894. PubMed ID: 29270749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.